A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Study sponsor: Definium Therapeutics US, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-09Estimated
Enrollment · participants165Estimated
Source updated2026-11-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.